Thromboembolism – Pipeline Review, H1 2018

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thromboembolism – Pipeline Review, H1 2018, provides an overview of the Thromboembolism (Cardiovascular) pipeline landscape.

When a blood clot (thrombus) breaks and travels in the blood, this is called a thromboembolism. Symptoms include warmth, edema, and erythema, and may also include dilated veins (collaterals) on the chest wall or leg. Risk factors include hypertension, diabetes mellitus, cigarette smoking, and high cholesterol levels. Treatment includes anticoagulants, thrombolytic therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thromboembolism – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Thromboembolism (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thromboembolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Thromboembolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, IND/CTA Filed and Preclinical stages are 3, 4, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Thromboembolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Thromboembolism (Cardiovascular).

– The pipeline guide reviews pipeline therapeutics for Thromboembolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Thromboembolism (Cardiovascular) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Thromboembolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Thromboembolism (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Thromboembolism (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Thromboembolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Bayer AG

China Biologic Products Inc

Daiichi Sankyo Co Ltd

F. Hoffmann-La Roche Ltd

Green Cross Corp

Ionis Pharmaceuticals Inc

Johnson & Johnson

Portola Pharmaceuticals Inc

Verseon Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Thromboembolism - Overview

Thromboembolism - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Thromboembolism - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Thromboembolism - Companies Involved in Therapeutics Development

Bayer AG

China Biologic Products Inc

Daiichi Sankyo Co Ltd

F. Hoffmann-La Roche Ltd

Green Cross Corp

Ionis Pharmaceuticals Inc

Johnson & Johnson

Portola Pharmaceuticals Inc

Verseon Corp

Thromboembolism - Drug Profiles

antithrombin III (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-1213790 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

betrixaban - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

edoxaban tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GCC-2107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONIS-FXIRx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-9375 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lysimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Thromboembolism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAP-ANV - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRX-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VE-2851 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YG-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Thromboembolism - Dormant Projects

Thromboembolism - Discontinued Products

Thromboembolism - Product Development Milestones

Featured News & Press Releases

Dec 19, 2017: FDA Approves Prior Approval Supplement for Commercial Launch of Portola Pharma's Novel Oral Anticoagulant Bevyxxa (betrixaban)

Dec 13, 2017: Once-Daily, Oral LIXIANA (edoxaban) Met Primary Endpoint in Investigational Hokusai-VTE CANCER Study

Dec 12, 2017: Portola Pharmaceuticals Provides Update on European Marketing Authorization Application for Betrixaban

Nov 30, 2017: Portola Pharmaceuticals to Present New Data on Betrixaban at the 59th American Society of Hematology (ASH) Annual Meeting

Nov 21, 2017: Portola Pharmaceuticals Provides Update on Bevyxxa (betrixaban) Commercial Launch

Nov 07, 2017: Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data on Betrixaban to be Presented at the America Heart Association Scientific Sessions 2017

Aug 21, 2017: Portola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban at the European Society of Cardiology (ESC) Congress 2017

Jun 23, 2017: FDA approved betrixaban (BEVYXXA, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients

Mar 13, 2017: Daiichi Sankyo Announces Large-scale Registry of Venous Thromboembolism in Cancer Patients

Mar 07, 2017: Portola Pharmaceuticals Announces Betrixaban Presentations at ACC.17

Feb 08, 2017: FDA Informs Portola Pharmaceuticals at Mid-Cycle Review for Betrixaban That It Has Not Identified Issues that Require an Advisory Committee Meeting

Dec 23, 2016: Portola Pharmaceuticals Announces FDA Accepts New Drug Application for Priority Review and EMA Validates Marketing Authorization Application for Oral, Factor Xa Inhibitor Anticoagulant Betrixaban

Dec 08, 2016: Daiichi Sankyo Announces Initiation of Real-World Study in LIXIANA (edoxaban) Patients Undergoing Diagnostic and Therapeutic Procedures in NVAF and VTE

Dec 06, 2016: ASH 2016: Explaining the lower bleeding risk of Verseon’s anticoagulants

Nov 28, 2016: Portola Pharmaceuticals Announces Betrixaban Data to be Presented at 2016 American Society of Hematology Annual Meeting and Exposition

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Thromboembolism, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Thromboembolism – Pipeline by Bayer AG, H1 2018

Thromboembolism – Pipeline by China Biologic Products Inc, H1 2018

Thromboembolism – Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Thromboembolism – Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Thromboembolism – Pipeline by Green Cross Corp, H1 2018

Thromboembolism – Pipeline by Ionis Pharmaceuticals Inc, H1 2018

Thromboembolism – Pipeline by Johnson & Johnson, H1 2018

Thromboembolism – Pipeline by Portola Pharmaceuticals Inc, H1 2018

Thromboembolism – Pipeline by Verseon Corp, H1 2018

Thromboembolism – Dormant Projects, H1 2018

Thromboembolism – Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Thromboembolism, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports